UPDATE: Citi Downgrades Amarin Corporation (AMRN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
MKM Lowers Fair Value, Adjusts Estimates on Amarin (AMRN) Following Q1 Results
May 12, 2014 12:19 PM EDTMKM Partners is lowering its fair value estimate on Amarin (Nasdaq: AMRN) from $2 down to $1.50, while maintaining the stock at Neutral.
Analyst Jon LeCroy commented, Vascepa prescriptions are again growing and the Kowa co-promote, scheduled to begin this month, is... More
Second-Half Vascepa Sales Growth Still in Focus for Amarin (AMRN); Aegis Maintains at 'Hold'
May 12, 2014 9:31 AM EDTAegis Capital maintains its Hold rating and $2 price target on Amarin Corp. (Nasdaq: AMRN) following Q1 results reported last week.
Analyst Ram Selvaraju Vascepa sales came in lighter than expected at $1.1 million, though R&D expenses of $11.7 million compared with the analysts... More
Amarin Corp Plc (AMRN) Posts Q1 Loss of 16c/Share; Updates on Ops
May 9, 2014 7:03 AM EDTAmarin Corp Plc (NASDAQ: AMRN) reported Q1 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.65 million.
Operational update
Commercialization and regulatory update
Amarin is now available on formulary to over 200 million lives in the United States, including over 100 million with Tier 2 coverage. As the company works to continue to increase the productivity of our sales representatives and work with our new co-promotion partner, Kowa Pharmaceuticals America, the company believes Vascepa sales will continue to... More
